BerGenBio presents preliminary Phase II clinical data at EHA 24: bemcentinib in combination with low dose chemotherapy yields durable responses in AML patients unfit for intensive chemotherapy
· Two posters to be presented at the 2019 annual congress of the European Hematology Association on 14th June · Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly acute myeloid leukaemia (AML) patients unfit for intensive chemotherapy shows significant efficacy · Preliminary responses reported in 6/14 (43%) patients, with CR/CRi in 4/14 (29%) patients; this is substantially higher than previously observed/historical benchmarks in single-agent cytarabine (low-dose chemotherapy) · Median relapse-free survival 7.9 months in CR/CRi patients (